PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143353
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143353
Pneumonia Therapeutics market size was valued at US$ 2,780.1 Million in 2025, expanding at a CAGR of 9.9% from 2026 to 2033.
Pneumonia Therapeutics refers to the medicines and therapeutic approaches used in treating pneumonia. The treatments involve the use of medicines to treat, prevent, and cure the illness. The treatment of pneumonia usually uses antibiotics such as macrolides, quinolones, or broad-spectrum beta-lactams for cases of bacterial pneumonia; antivirals for cases of viral pneumonia; and supportive medications such as oxygen therapies, bronchodilators, corticosteroids, and intravenous fluids. The administration of pneumonia therapeutics can be through the oral route, intravenously, and through inhalation, and this depends on many factors, including the degree of the disease, the nature of the infection, the age of the individual, and the condition of the patient. This makes pneumonia therapeutics one of the most important parts in any setting where there is a disease, including the hospital and intensive care unit settings.
Pneumonia Therapeutics Market- Market Dynamics
Increasing Prevalence Of Pneumonia To Drive Market Growth
The increasing prevalence of pneumonia is driving the demand for effective pneumonia therapeutics, because as more and more patients come up with the disease, there will be the need for appropriate treatment and management. For example, in February 2026, it was revealed by Asthma + Lung UK Org that emergency admission of patients suffering from pneumonia in hospitals in England alone grew to 579,475 as compared to 461,995 cases, representing an increase of 25.4% in two years. There were 567,760 cases of pneumonia. This rising disease burden is expected to increase demand for effective pneumonia therapeutics and treatment options.
The Global Pneumonia Therapeutics market is segmented on the basis of Product, Infection, Route of Administration, End Use, and Region.
Drugs play an important part in the therapeutics market of pneumonia due to their efficiency in treating bacteria, fungal, and viral infections, given that there are a lot of drugs available for the treatment of pneumonia ranging from mild to severe pneumonia. The market includes a range of drugs, such as antibiotics, antivirals, and antifungals, among others, that are employed in the treatment of pneumonia and help prevent complications due to pneumonia infections. In July 2025, Sanofi acquired Vicebio and two vaccines from it, namely VXB-241, which is a bivalent vaccine for RSV and hMPV, and VXB-251, which is a preclinical tripartite vaccine for the two viruses. The two viruses cause lower respiratory tract infections, including pneumonia. These developments are expected to support drug adoption for preventing and treating pneumonia-related respiratory infections.
The Community-acquired pneumonia (CAP) is the key segment in the Pneumonia Therapeutics market since there are a number of incidences of pneumonia in the community and there is a need to develop effective antibiotics and other treatments for the management of the disease in the patients. In July 2026, F. Hoffmann-La Roche Ltd. introduced zosurabalpin, which is an innovative antibiotic for the treatment of severe pneumonia caused by drug-resistant Gram-negative bacteria. The company stated that pneumonia is one of the serious infections that can be managed using the antibiotic drug. These developments will drive the demand for new therapies to treat severe cases of community-acquired pneumonia.
Pneumonia Therapeutics Market- Geographical Insights
The Pneumonia Therapeutics market in North America is backed up by some of the key advancements in diagnostic technologies and treatments. For example, in September 2026, per the U.S. Food and Drug Administration (gov), there are more than 1,600 FDA-cleared medical devices in use as of September 2026 in the U.S. that utilize artificial intelligence design in order to enhance diagnostics through early detection and medical diagnosis of diseases, personalized health care diagnostics and decisions, and treatments. FDA gives an example of using such technology through the application of AI-based imaging tools for detecting skin cancer, pap smear and eye images for detecting diabetes retinopathy, and a deep learning software to improve the quality of the picture. The use of such devices would drive innovations in AI-based diagnostic technologies in the U.S. healthcare industry.
The competitive landscape is characterized by key competitors' focus on product development, strategic acquisitions, and geographical expansion. The main players in this industry are Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd., and Merck & Co., Inc. Some of the strategies followed by the main companies in the industry include business development and geographic expansion. For instance, in March 2025, Merck announced that its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE(R), has received approval from the European Commission to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults age 18 years and older. Such strategies are helping in improving the product portfolio of key market participants.
In January 2025, Roche advanced zosurabalpin, an investigational antibody that works on Gram-negative bacteria, which are the cause of various infections, such as pneumonia, to late-stage clinical development in order to develop a novel therapeutic option for drug-resistant bacterial infections.